1upHealth
Boston, MA | www.1up.health
1upHealth helps payers, providers, and digital health companies build an end-to-end FHIR data strategy that is enabled by best-in-class tools on a scalable, serverless, and secure platform.
Healthcare and
Life Sciences
View All Announcements
Our Approach
Strategic Capital and Tailored Solutions
Our team of seasoned healthcare investors provides strategic and often non-dilutive capital tailored to healthcare and pharma business timelines, whether to develop or launch new medicines, acquire assets, or provide growth capital to finance strategic initiatives.
Long-Term Partnerships
We are passionate about forming long-term partnerships with companies creating new technologies to address our most pressing healthcare challenges and improve patient care. Our experienced life sciences and technology teams focus on collaborating to develop AI and software-related themes within the healthcare space.
Broad Sector Expertise
We invest across the sector and have partnered with companies in drug development and marketing, devices and diagnostics, generics, pharma and healthcare business services, and contract research, development and manufacturing.
Healthcare IT and Software
Healthcare Data and AI
OTC, Consumer, Cosmeceuticals
Pharma Services, CROs, CDMOs, Life Science Tools
Medical Devices
Diagnostics
Pharmaceuticals and Biotechnology
Consumer Services
HEALTHCARE and LIFE SCIENCES
Our Solutions
Working with both private and public companies, our custom financing solutions include and often combine common equity, convertible preferred equity, redeemable preferred equity, or convertible debt.
Case Study: Caris Life Sciences
We seek to work with companies about to commence commercial operations through to profitability with secured debt or debt-like financing. We can tailor terms and structure to reflect a company’s stage of growth.
Case Study: Biohaven
Our team can work with companies on either passive royalty financings (company receives a passive third-party and typically non-dilutive royalty) or synthetic royalty financings (company creates royalty on its own product). Royalty financings can include traditional royalty purchases, structured royalty acquisitions (including annual or cumulative caps), or royalty-backed debt.
Case Study: Immunogen
We can work directly with companies to help bring new products or therapies to the market. Our structures can help companies achieve their financial, accounting, and strategic aims all while retaining control of the development of their assets.
We have worked directly with healthcare funds to help fund the exit of assets at the end of fund life, acquire earnouts, or help fund incremental investments post-LP commitment period. We can transact at the fund or asset level.
SELECT INVESTMENTS
Beginning in 2020, Sixth Street provided $750 million in non-dilutive financing to support the commercial launch of or Nurtec® ODT, the first FDA-approved oral medicine for the prevention and treatment of migraines. On May 10, 2022, Pfizer announced its acquisition of Biohaven for $11.6 billion.
Learn More
SELECT INVESTMENTS
Sixth Street led a combined $1.25 billion strategic financing for Blueprint Medicine, a biopharmaceutical company with a proven track record of success in developing and commercializing precision therapies to broad patient populations through internal R&D and strategic business development.
Learn More
SELECT INVESTMENTS
In 2021, Sixth Street made a strategic investment in Datavant, a leading healthcare data platform dedicated to helping protect, match, and share health data.
Learn More
SELECT INVESTMENTS
Since first investing in 2018, Sixth Street has invested over $450 million of growth capital in Caris Life Sciences, a leading innovator in molecular science and technology developing the next generation of precision oncology profiling.
Learn More
SELECT INVESTMENTS
In 2020, Sixth Street invested in MDLIVE, one of the fastest growing telehealth providers of online and on-demand healthcare delivery services and software platforms in the United States. MDLIVE was acquired by Cigna’s Evernorth in 2021.
Learn More
SELECT INVESTMENTS
In September 2021, Sixth Street invested in the Series D for Mammoth Biosciences, a biotech company co-founded by Nobel laureate Jennifer Doudna that is building the next generation of CRISPR products in therapeutics and diagnostics.
